Recent News

• 04.14.2025 - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
• 04.14.2025 - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
• 04.14.2025 - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
• 03.27.2025 - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
• 03.27.2025 - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
• 03.27.2025 - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
• 02.24.2025 - Inhibikase Announces Expansion of Senior Leadership Team
• 02.24.2025 - Inhibikase Announces Expansion of Senior Leadership Team
• 02.24.2025 - Inhibikase Announces Expansion of Senior Leadership Team

Recent Filings

• 04.14.2025 - 8-K Current report
• 04.14.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.25.2025 - 3 Initial statement of beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities